Background
Amitiza (lubiprostone) is a prescription drug approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Takeda Pharmaceuticals and its predecessor Sucampo Pharmaceuticals held the drug’s patents and marketed it exclusively for years at brand-name prices. When Par Pharmaceutical sought FDA approval to market a generic version, the companies did not litigate the patent dispute to conclusion. Instead, in 2014 they entered a settlement under which Par agreed to delay its generic entry until January 1, 2021 — while receiving a profit-sharing arrangement on an authorized generic that effectively functioned as a payment for the delay. This type of arrangement — a brand drugmaker paying a generic competitor to stay off the market — is known as a “pay-for-delay” or “reverse payment” settlement.
Classes of direct purchasers (wholesalers), indirect purchasers (retailers), and end payors sued Takeda and Sucampo, arguing the 2014 settlement violated the federal Sherman Antitrust Act by unlawfully extending Takeda’s market exclusivity and forcing purchasers to pay higher prices for Amitiza during a period when a generic could and should have been available. The case reached trial in May 2026.
The Court’s Holding
On May 18, 2026, a federal jury in Boston found Takeda (and Sucampo) liable for entering into an anticompetitive reverse-payment settlement with Par Pharmaceutical. The jury awarded damages totaling $884,943,990 in single damages across the plaintiff classes — $474.9 million to the direct-purchaser wholesaler class, $346.8 million to individual retailers, and $65 million to end payors subject to further proceedings. Under the Sherman Act, antitrust damages are automatically trebled, putting the total exposure for Takeda at approximately $2.6 billion before appeals and any adjustments.
This verdict is the first in U.S. history to find a pharmaceutical company liable for a pay-for-delay reverse-payment settlement following the Supreme Court’s landmark FTC v. Actavis decision in 2013. In Actavis, the Court held that such settlements can violate antitrust law when the payment is “large and unjustified” — but left the liability determination to lower courts and juries on a case-by-case basis. The Amitiza jury is the first to conclude that a specific settlement crossed that line. Takeda announced it intends to appeal, citing “evidentiary and legal errors” it alleges occurred at trial.
Key Takeaways
- This is the first jury verdict holding a pharmaceutical company liable under the pay-for-delay antitrust theory established in FTC v. Actavis (2013) — a watershed thirteen years in the making.
- The $884.9 million single-damages award trebles automatically to more than $2.6 billion under the Sherman Act, creating an existential damages exposure that will reshape how pharmaceutical companies evaluate patent settlement terms.
- The verdict targeted the “authorized generic” profit-sharing structure that Takeda used — a common mechanism many drug companies have used in patent settlements — putting that approach directly in the crosshairs of antitrust scrutiny.
- Takeda’s appeal will likely challenge both the evidentiary standards applied at trial and the sufficiency of the jury’s finding that the payment was “large and unjustified” under the Actavis framework.
Why It Matters
The pharmaceutical industry has operated in the shadow of FTC v. Actavis for over a decade, but no jury had ever actually imposed liability — until now. The Amitiza verdict removes any remaining complacency. Pay-for-delay settlements — long used as a routine tool to avoid costly patent litigation — now carry the demonstrated risk of billion-dollar jury verdicts. The decision will force pharmaceutical companies to fundamentally re-examine how they structure Hatch-Waxman patent settlements with generic drug manufacturers.
For IP and antitrust practitioners, the verdict also signals that juries can and will apply the Actavis “rule of reason” analysis to evaluate whether a given payment was anticompetitive. The case will likely generate significant appellate litigation on the appropriate jury instructions and evidentiary standards for pay-for-delay cases — making the First Circuit’s eventual ruling on Takeda’s appeal another landmark to watch.